Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | July 16, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.80 · Expires 2029-09-09 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Gift · Disposed 29,555 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F2: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.53 · Expires 2030-06-02 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-16 · Gift · Disposed 14,777 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F4: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.37 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-16 · Gift · Disposed 11,650 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F5: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-16 · Gift · Disposed 21,000 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F6: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.46 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-16 · Gift · Disposed 19,441 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F7: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.41 · Expires 2034-06-04 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-16 · Gift · Disposed 7,639 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F8: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2035-06-02 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-07-16 · Gift · Disposed 29,747 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F9: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-07-16 · Gift · Disposed 17,786 · Balance 0 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F10: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.80 · Expires 2029-09-09 | IndirectBy Trust | 29,555 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Gift · Acquired 29,555 · Balance 29,555 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F2: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.53 · Expires 2030-06-02 | IndirectBy Trust | 14,777 |
Reported balance
After 2026-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-16 · Gift · Acquired 14,777 · Balance 14,777 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F4: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.37 · Expires 2031-06-07 | IndirectBy Trust | 11,650 |
Reported balance
After 2026-07-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-16 · Gift · Acquired 11,650 · Balance 11,650 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F5: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2032-06-06 | IndirectBy Trust | 21,000 |
Reported balance
After 2026-07-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-16 · Gift · Acquired 21,000 · Balance 21,000 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F6: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.46 · Expires 2033-06-12 | IndirectBy Trust | 19,441 |
Reported balance
After 2026-07-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-16 · Gift · Acquired 19,441 · Balance 19,441 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F7: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.41 · Expires 2034-06-04 | IndirectBy Trust | 7,639 |
Reported balance
After 2026-07-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-07-16 · Gift · Acquired 7,639 · Balance 7,639 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F8: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2035-06-02 | IndirectBy Trust | 29,747 |
Reported balance
After 2026-07-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-07-16 · Gift · Acquired 29,747 · Balance 29,747 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F9: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | IndirectBy Trust | 17,786 |
Reported balance
After 2026-07-16 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-07-16 · Gift · Acquired 17,786 · Balance 17,786 F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. F10: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date. F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.
F2: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.
F3: The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.
F4: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.
F5: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.
F6: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.
F7: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.
F8: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.
F9: This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.
F10: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 136,301 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 9,398 · Balance 0 F3: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 148,063 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). F2: Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the Reporting Person is the manager. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2034-06-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 26,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.83 · Expires 2033-06-23 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2032-06-02 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.32 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.20 · Expires 2030-06-01 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.97 · Expires 2029-11-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-09 · Disposition to issuer · Disposed 26,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: Represents shares held directly by Les Pommes, LLC, a family limited liability company for which the Reporting Person is the manager. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2022 Filed Oct 27, 2022 21:50 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 11,539 | $43.97 | $507,426.37 |
DisclosureSEC source: 0000899243-22-034377 · doc4.xml · nonDerivative · entry 4 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,452 F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive. F2 · balance_after: The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution"). F3 · balance_after: (Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 21:50 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 35,860 | $43.08 | $1,544,691.02 |
DisclosureSEC source: 0000899243-22-034377 · doc4.xml · nonDerivative · entry 3 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,991 F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive. F2 · balance_after: The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution"). F3 · balance_after: (Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 21:50 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 4,906 | $44.92 | $220,359.37 |
DisclosureSEC source: 0000899243-22-034377 · doc4.xml · nonDerivative · entry 2 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 326,813 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4. F2 · balance_after: The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution"). F3 · balance_after: (Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution. F4 · ownership.nature: Represents shares held directly by the LLC. The reporting person is the manager of the LLC. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 21:50 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 4,515 | $44.92 | $202,797.09 |
DisclosureSEC source: 0000899243-22-034377 · doc4.xml · nonDerivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,851 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4. F2 · balance_after: The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution"). F3 · balance_after: (Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001209191-22-035077 · doc4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:25 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0000899243-22-020953 · doc4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| June 08, 2021 Filed Jun 25, 2021 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $40.37 | $0.00 |
DisclosureSEC source: 0001209191-21-043330 · doc4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. F2 · ownership.direct: Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:56 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0001104659-21-076498 · tm2118278-4_4seq1.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:03 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | PurchaseCommon Stock | 375,000 | $39.00 | $14,625,000.00 |
DisclosureSEC source: 0001209191-20-060543 · doc4.xml · nonDerivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L.P. Disclosed balance after: 17,161,713 F1 · ownership.nature: Represents shares held by Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III") is the sole general partner of ATP IV. The reporting person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV, but disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 16:45 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 415,000 | $36.00 | $14,940,000.00 |
DisclosureSEC source: 0001104659-20-083453 · a4.xml · nonDerivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,830,203 F1 · shares: On July 10, 2020, Apple Tree Partners IV, L.P. ("ATP") purchased 415,000 shares of common stock of the Issuer at a price of $36.00 per share pursuant to an underwritten public offering. These shares are owned directly by ATP. F2 · ownership.nature: These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 14,777 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001209191-20-034729 · doc4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,777 Underlying: Common Stock · 14,777 shares Expires 2030-06-02 F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. F2 · ownership.direct: Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $25.20 | $0.00 |
DisclosureSEC source: 0001104659-20-069071 · a4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. F2 · ownership.direct: Under the Reporting Person's arrangement with Apple Tree Venture Management, LLC (the "Management Company"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Management Company any net cash received upon exercise of the option and sale of the underlying common stock, which will offset management fees owed by the Fund to the Management Company. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 19:03 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001104659-19-062784 · a4.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2029-11-07 F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019. F2 · ownership.direct: Under the Reporting Person's arrangement with Apple Tree Venture Management, LLC (the "Management Company"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Management Company any net cash received upon exercise of the option and sale of the underlying common stock, which will offset management fees owed by the Fund to the Management Company. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| September 10, 2019 Filed Sep 13, 2019 00:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 29,555 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0001567619-19-018225 · doc1.xml · derivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,555 Underlying: Common Stock · 29,555 shares Expires 2019-09-09 F1 · derivative.exercise_date: This option shall vest (i) 1/12th of the total shares on June 21, 2019; and then (ii) quarterly as to 1/12th of the total shares, commencing the first quarter following June 21, 2019, subject to Reporting Person's continued service through each vesting date. F2 · ownership.direct: Under the Reporting Person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:05 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionSeries B Preferred Stock · Derivative | 880,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037458 · a4.xml · derivative · entry 5 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 286,439 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.nature: These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:05 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionSeries A Preferred Stock · Derivative | 13,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037458 · a4.xml · derivative · entry 4 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,228,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.nature: These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:05 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 900,000 | $16.00 | $14,400,000.00 |
DisclosureSEC source: 0001104659-19-037458 · a4.xml · nonDerivative · entry 3 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,415,203 F5 · shares: On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F4 · ownership.nature: These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:05 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionCommon Stock | 286,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-037458 · a4.xml · nonDerivative · entry 2 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,515,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.nature: These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 18:05 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionCommon Stock | 4,228,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-037458 · a4.xml · nonDerivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,228,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. ("ATP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.nature: These shares are owned directly by ATP. The Reporting Person is a principal of the general partner of ATP and disclaims beneficial ownership of the shares held by ATP, except to the extent of his pecuniary interest therein. The Reporting Person has sole voting and investment control and power over the shares held by ATP. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,799,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · derivative · entry 7 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 0 Underlying: Common Stock · 2,799,910 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 7,617,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · derivative · entry 6 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 0 Underlying: Common Stock · 7,617,746 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,980,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · derivative · entry 5 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 0 Underlying: Common Stock · 4,980,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | PurchaseCommon Stock | 1,388,889 | $18.00 | $25,000,002.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · nonDerivative · entry 4 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 16,786,713 F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionCommon Stock | 2,799,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · nonDerivative · entry 3 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 15,397,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionCommon Stock | 7,617,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · nonDerivative · entry 2 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 12,597,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 21:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | ConversionCommon Stock | 4,980,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013840 · doc1.xml · nonDerivative · entry 1 Harrison Seth Loring · CIK 0001404955 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Apple Tree Partners IV, L. P Disclosed balance after: 4,980,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F1 · price: The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019. F2 · ownership.nature: Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Reporting Person is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.